Member Info for inanaco

yea great ... take another dilution .. throw as much money as possible at it ... but until you have a phase 2 under your belt saying ... it works better than the competition ... or updates to say its working ... you aint got nothing. and the lead product here has still to go through another phase 1 trial with the addition of Chemo ... are you blind ? all i can say The Truth Hurts ... best of luck chap

if you actually took the time to read what i posted rather than kick off !! you will appreciate what i had written !

which is exactly what i was trying to point out yesterday ... this extra trial will determine if they can get the cancer destroyed by adding chemo. hence the second cohort, and how will it be funded

thats made the SP jump a bit..

Not a problem for me ... as the share i am in has a clear defined path ... best of luck...

its from SLN .................. RNS ... not the lancet ... leave it with you .. best of luck if your invested ... I am sure the charting boys can put all this into there figures ... but first you need to find them ...

you need to research this share 100% before you pass comment m8 ... words like potential fundraising !! this is your lead product ... its getting results in 1/3rd of patients ... but it has to be run with chemo .. as yet there is no trial date or how your going to fund it ... which is why i mentioned how much cash will roll in from the phase 2 deals already signed ? and where is this cash going ... will it be used to fund a second phase 1 cohort ? if so will it fund a phase 2 if it works against all the competition in this sector ... which again you have not researched

Phase I data for Atu027 and Potential Fundraising Wed, 6th Jun 2012 12:00 FOR IMMEDIATE RELEASE Silence Therapeutics Announces Safe and Effective Dose Successfully Identified in Phase I Study of Atu027 and Potential Fund Raising London, June 6, 2012 - Silence Therapeutics plc (AIM: SLN) ("Silence" or the "Company"), a leading global RNA interference (RNAi) therapeutics company, on Monday presented the latest data from its ongoing Phase I study of Atu027, its lead internal therapeutics candidate, alongside the 2012 American Society of Clinical Oncology ("ASCO") Annual Meeting in Chicago, Illinois. At this meeting, Klaus Giese, Ph.D., Silence's Chief Scientific Officer and the study's principal investigator Dr. Dirk Strumberg, Professor of Medicine and Director of Department of Hematology and Medical Oncology at University of Bochum (Marienhospital Herne, Germany), gave an update and discussed the data from the Atu027 Phase I trial. Silence's open label, single-centre, dose-finding Phase I study of Atu027 in subjects with advanced solid cancer was designed to evaluate up to a total of 11 escalating doses of Atu027. The enrolment of patients in the last cohort in dose level 10 has been completed and last treatment is scheduled on 22nd of June 2012. Atu027 was very well tolerated and safe up to the 10th dose level. No premedication was needed in support of Atu027 treatment. The prospective recommended maximum tolerated dose is 0.336 mg/kg. "Stable disease" response for three and six months after treatment was observed in 10 and 3 patients, respectively, of the 33 evaluable patients. Two patients with neuroendocrine cancer had disease stabilisation for 9 and 12 months. Partial regression of pulmonary metastases was found in another patient. A further patient with breast cancer showed regression of liver metastases.

Tumours At 2012 ASCO Annual Meeting London, May 17, 2012 - Silence Therapeutics plc (AIM: SLN) ("Silence" or the "Company"), a leading global RNA interference (RNAi) therapeutics company, today announces that top line data from its ongoing Phase I trial of Atu027 show that of the 33 patients treated in the first 10 cohorts of the study, 10 patients experienced stable disease after three months. Two patients with neuroendocrine cancers had disease stabilisation for nine and 12 months respectively, including partial regression of liver metastases in one patient. Another patient with breast cancer demonstrated regression of liver metastases. Importantly, among various biomarkers tested, sVEGFR-1 plasma levels decreased significantly upon treatment further confirming a potential biological effect of Atu027.

Yes thats the one that holds the big value ... thats why they raised all this cash ... thats an inhibitor like SAR study that one ... and place it in the market ... if you can do that like i did with Immunobody ... great you add value here ... all companies have to invest in a product ... but not many make it to the market ... the trick is not to be blown away by clever Scientists ... as they still get paid ... but how does the investor ?... work that out and you make big money !!! if you dont you will lose your shirt ... as for bids for the company ............FOR IMMEDIATE RELEASE Potential Offer London, 6 September, 2010 - Silence Therapeutics plc (AIM: SLN) notes the recent share price movement and announces that it has received an approach which may or may not lead to an offer for the Company. A further announcement will be made in due course.

yea ... they where talking with SAR ... i wonder why they didn't listen to him .... and come to that why have they not signed up for your lead product ? it has 1 trial under its belt. which is what this discussion is about ...

well read back .... and ask your shareholders to stump up $1 billion ... lol

your starting to post nonesense ... and so is Jon510 ... leave it with you ... shareholders and buyers here can work it out for themselves ...

how does that answer my questions ... nothing to do with the technology ....

I have not lost anything ... only paper profit ... but i can see a multiple reason's to hold SCLP ... show me the reason to hold SLN and why ... why dont you answer my Questions... and for that matter any shareholder here ... thats your worry not mine ...

why you asking me on here ... this is SLN ... why dont you answer the questions put to you ...about SLN ... the share dropped from 7p ... which is nothing to do with me, prehaps the main posters on here could assist ?

nothing ... Ichor was granted options for shares

i never posted here like this till after the SP slide ... so what happened to 7p ? to 4.2p ? was that the inanaco effect from not posting ?

all markets are weak at the moment ... if the share has strength it will recover .. what you have to do is convince shareholders of the value here not me ...

only posting facts mate ... a share holder here asked advice .. what should i do ... tell him to DYOR .. your so happy to give your advice ... mainly on me rather than the share ...